Station Casinos Inc. (STN)

All Comments on STN

  • commenter
    SeekingAlpha
    Editors
    Apr 06 05:18 AM
    My Website
    General Discussion on STN
    Is this a buy or a sell? Reply
  • commenter
    WC Whiner
    Oct 05 12:10 AM
    My Website
    Valuing the Casino Industry: Are There More Harrah's Out There? [view article]
    Valuation and the market's perceptions matter, too. Here's your table from 2.5 up with price/sales and short ratio:
    cpx/s p/s sr
    cnty 14.4 5.5 20.9
    lvs 11.7 12.1 2.9
    stn 8.5 3.0 6.3
    uwn 4.4 5.0 5.4
    meca 4.1 0.8 21.1
    wynn 3.6 6.3 7.5
    byd 3.5 1.5 5.1
    het 2.7 1.5 2.7
    pnk 2.6 1.6 4.3
    isle 2.5 0.7 4.6

    HET appears to have been a case with comparatively rational valuation and few reservations from the market. Even BYD has double the short interest, and north of that you either have some multiple of HET's price/sales, or of its short ratio, or of both.

    That's to say nothing of the only real risk in the casino business: overbuilding.     Reply
  • commenter
    jolly singh
    Jul 16 11:18 AM
    My Website
    One Page Barron's Summary [view article]
    Great website found first time and great Information. Where were u guys hiding? Reply
  • commenter
    Asif
    Jun 25 09:13 PM
    My Website
    One Page Barron's Summary [view article]
    Probably the following statement by the CEO Antonio Perez during the Kodak conference call when asked whether Kodak was on track for back to school <i>"I never said we’re going to be back to school. We’re still on track with our project. We are — I have no news really to report, and you know why I don’t want to report news until the closest possible time, the latest possible time. So but we keep investing in that business. We are accelerating things and I feel that we are in good shape, but there is nothing else to report."</i>...

    It is interesting to see the generic drug maker Teva (TEVA) back where it was a year ago. The run-up that started last year was in anticipation on looming patent expirations at big pharma companies like Pfizer (PFE) and Merck. I feel that the Zocor pricing move by Merck is likely to be negative for the generic drug companies like Teva, Ranbaxy, Mylan and Dr. Reddy's but would barely affect Pfizer. Pfizer raised its dividend about six months ago and I doubt they would do it again anytime soon.     Reply

Trading Center


Loading...
Symbols:
Authors:
Quick Links: